SOD2, superoxide dismutase 2, 6648

N. diseases: 668; N. variants: 32
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.370 Biomarker group CTD_human The effect of superoxide anion and hydrogen peroxide imbalance on prostate cancer: an integrative in vivo and in vitro analysis. 26468117 2015
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.370 Therapeutic group CTD_human The effect of superoxide anion and hydrogen peroxide imbalance on prostate cancer: an integrative in vivo and in vitro analysis. 26468117 2015
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.370 Therapeutic group CTD_human Association between gene polymorphism of manganese superoxide dismutase and prostate cancer risk. 23315858 2013
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.370 Biomarker group CTD_human Association between gene polymorphism of manganese superoxide dismutase and prostate cancer risk. 23315858 2013
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.370 Biomarker group CTD_human Heterocyclic aromatic amine [HCA] intake and prostate cancer risk: effect modification by genetic variants. 22564066 2012
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.370 Therapeutic group CTD_human Heterocyclic aromatic amine [HCA] intake and prostate cancer risk: effect modification by genetic variants. 22564066 2012
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.370 Therapeutic group CTD_human In a low-selenium population, SOD2-Ala16+ men homozygous for SEPP1-Ala234 are at an increased risk of prostate cancer/aggressive prostate cancer especially if ever-smokers, because they are likely to produce more mitochondrial H(2)O(2) that they cannot remove, thereby promoting prostate tumor cell proliferation and migration. 19074884 2008
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.370 GeneticVariation group LHGDN Association of prostate cancer and manganese superoxide dismutase AA genotype influenced by presence of occult cancer in control group. 18571701 2008
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.370 Biomarker group BEFREE In a low-selenium population, SOD2-Ala16+ men homozygous for SEPP1-Ala234 are at an increased risk of prostate cancer/aggressive prostate cancer especially if ever-smokers, because they are likely to produce more mitochondrial H(2)O(2) that they cannot remove, thereby promoting prostate tumor cell proliferation and migration. 19074884 2008
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.370 Biomarker group CTD_human Effects of manganese superoxide dismutase silencing on androgen receptor function and gene regulation: implications for castration-resistant prostate cancer. 18829485 2008
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.370 Therapeutic group CTD_human Effects of manganese superoxide dismutase silencing on androgen receptor function and gene regulation: implications for castration-resistant prostate cancer. 18829485 2008
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.370 GeneticVariation group LHGDN Manganese superoxide dismutase (MnSOD) gene polymorphism, interactions with carotenoid levels and prostate cancer risk. 18784358 2008
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.370 Biomarker group CTD_human In a low-selenium population, SOD2-Ala16+ men homozygous for SEPP1-Ala234 are at an increased risk of prostate cancer/aggressive prostate cancer especially if ever-smokers, because they are likely to produce more mitochondrial H(2)O(2) that they cannot remove, thereby promoting prostate tumor cell proliferation and migration. 19074884 2008
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.370 Therapeutic group CTD_human Functional variant of manganese superoxide dismutase (SOD2 V16A) polymorphism is associated with prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer study. 17646272 2007
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.370 GeneticVariation group LHGDN Functional variant of manganese superoxide dismutase (SOD2 V16A) polymorphism is associated with prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer study. 17646272 2007
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.370 Therapeutic group CTD_human Effects of manganase superoxide dismutase Ala-9Val polymorphism on prostate cancer: a case-control study. 17465268 2007
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.370 GeneticVariation group LHGDN Effects of manganase superoxide dismutase Ala-9Val polymorphism on prostate cancer: a case-control study. 17465268 2007
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.370 Biomarker group CTD_human Functional variant of manganese superoxide dismutase (SOD2 V16A) polymorphism is associated with prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer study. 17646272 2007
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.370 Biomarker group CTD_human Effects of manganase superoxide dismutase Ala-9Val polymorphism on prostate cancer: a case-control study. 17465268 2007
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.370 AlteredExpression group LHGDN Overexpression of manganese superoxide dismutase promotes the survival of prostate cancer cells exposed to hyperthermia. 15512801 2004
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.370 Biomarker group LHGDN Increased manganese superoxide dismutase (SOD-2) is part of the mechanism for prostate tumor suppression by Mac25/insulin-like growth factor binding-protein-related protein-1. 12592389 2003
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.370 Biomarker group BEFREE Increased manganese superoxide dismutase (SOD-2) is part of the mechanism for prostate tumor suppression by Mac25/insulin-like growth factor binding-protein-related protein-1. 12592389 2003
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.370 Therapeutic group CTD_human Increased manganese superoxide dismutase (SOD-2) is part of the mechanism for prostate tumor suppression by Mac25/insulin-like growth factor binding-protein-related protein-1. 12592389 2003
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.370 Biomarker group CTD_human Increased manganese superoxide dismutase (SOD-2) is part of the mechanism for prostate tumor suppression by Mac25/insulin-like growth factor binding-protein-related protein-1. 12592389 2003